55687-34-8,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-34-8,6-Bromoquinoxalin-2(1H)-one,as a common compound, the synthetic route is as follows.
Example 16 1-(6-Bromoquinoxalin-2-yl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)propan-2-ol (38)To 6-bromoquinoxalin-2(1H)-one (250 mg, 1.11 mmol) was added POBr3 (500 mg, 2.61 mmol) at RT. The reaction mixture was gradually heated to 130 C. and stirred for 2 h. After completion of reaction (by TLC), the reaction mixture was cooled to 0 C., neutralized with satd NaHCO3 solution (50 mL) and extracted with EtOAc (2¡Á50 mL). The combined organic extracts were washed with H2O (50 mL) and brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude material. Purification by silica gel column chromatography (eluting with 10% EtOAc/hexane) afforded compound AI (160 mg, 0.55 mmol, 50%) as an off-white solid. 1H NMR (200 MHz, CDCl3): delta 8.84 (s, 1H), 8.30 (d, J=9.0 Hz, 1H), 7.96-7.82 (m, 2H).
As the paragraph descriping shows that 55687-34-8 is playing an increasingly important role.
Reference£º
Patent; VIAMET PHARMACEUTICALS, INC.; US2012/329802; (2012); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider